Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis

• DOI: 10.1111/hepr.12400
• Publication Date: 2014-08-04T03:17:08Z
• Authors: Noriaki Naeshiro; Hiroshi Aikata; Hideyuki Hyogo; Hiromi Kan; Hatsue Fujino; Tomoki Kobayashi; Takayuki Fukuhara; Yohji Honda; Takashi Nakahara; Atsushi Ohno; Daisuke Miyaki; Eisuke Murakami; Tomokazu Kawaoka; Masataka Tsuge; Nobuhiko Hiraga; Akira Hiramatsu; Michio Imamura; Yoshiiku Kawakami; Hidenori Ochi; Kazuaki Chayama
• Keywords: Portal vein thrombosis; Liver disease

To assess the efficacy and safety of anticoagulant drug, danaparoid sodium, in treatment portal vein thrombosis (PVT) patients with liver cirrhosis.A consecutive 26 cirrhotic PVT were enrolled this retrospective cohort study. The etiologies cirrhosis hepatitis B virus-related, C alcoholic cryptogenic five, 14, three four patients, respectively. Child-Pugh grade A, was noted 13, eight five Patients treated 2 weeks' administration sodium followed by evaluation reduction adverse events.All experienced through treatment. median volume before after 2.40 cm(3) (range, 0.18-16.63) 0.37 0-5.74), rate 77.3% 18-100%). According to rate, complete (CR), partial (PR, ≥50%) stable disease (SD, <50%) observed (15%), 16 (62%) six (23%), significantly different between CR + PR SD (2.09 vs 4.35 , P = 0.045). No severe events such as bleeding symptoms (e.g. gastrointestinal cerebral hemorrhage) thrombocytopenia encountered.Danaparoid for safe effective. Therefore, anticoagulation therapy could have potential one options accompanied cirrhosis.